Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
September 07, 2022 01:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients
August 22, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford...
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
July 29, 2022 16:05 ET
|
Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
July 18, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Insights on the Dermatology Diagnostic Devices Global Market to 2027 - by Product Type, End-use and Region
May 27, 2022 08:13 ET
|
Research and Markets
Dublin, May 27, 2022 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 10:47 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases
May 03, 2022 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832,...
Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine
April 28, 2022 08:00 ET
|
Mindera Health
San Diego, CA, April 28, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform - the first realization of precision medicine in psoriasis, has...
The Worldwide Skin Boosters Industry is Expected to Reach $1.5 Billion by 2027
April 26, 2022 07:43 ET
|
Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Skin Boosters Market Size, Share & Industry Trends Analysis Report By Type (Mesotherapy and Micro-needle), By Gender (Female and Male), By...
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 21, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...